Agilent Technologies: stocks, financial statements

Dividends News
Favorites

It is engaged in the production of measuring equipment, electronic medical equipment and equipment for chemical analysis. It also develops consumables and independently provides diagnostic services for the chemical composition of various food and medical products. For the state segment, food products are examined for the presence of various types of contamination (viruses, bacteria, chemicals, and microorganisms). In the energy industry, the company conducts research on biofuels as an alternative form of energy.

Environmental and criminal examination reveals the presence of metals, various biological additives and residues of medical drugs in athletes. Pharmaceutical diagnostics helps to create new medicines, check their purity and compliance with standards. Medical diagnostics mainly works in the field of Oncology, cardiovascular diseases, diabetes, but also allows you to quickly provide doctors with the necessary information on other diseases. Most of the company's product lines were developed by Hewlett-Packard.

  • A Ticker
  • NYSE Exchange
  • 14,800 Employees
11 rated
  • $145.01, $-1.91 (-1.30%) Previous Close
  • 3,220,663 Previous Volume
  • $84.20 / $147.68 52 week low / high
  • -0.51% Percent off 52 week high
  • 2021-06-18 Updated
  • 0.52% Dividend Yield (trailing)
  • 0.54% Dividend Yield (forward)
  • 0 Public float
  • 303,443,225 Outstanding shares
  • 48.20 P/E
  • 44.58 B Market Cap
Disable ads for free

Financial statements — Agilent Technologies

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 2020 2019 2018 2017 2016
Total Revenue
5.3B 5.2B 4.9B 4.5B 4.2B
Cost Of Revenue
2.5B 2.4B 2.2B 2.1B 2B
Gross Profit
2.8B 2.8B 2.7B 2.4B 2.2B
Research and Development
500M 400M 390M 340M 330M
Selling General and Admin
1.5B 1.5B 1.4B 1.2B 1.3B
Operating Expense
4.5B 4.2B 4B 3.6B 3.6B
Operating Income
850M 940M 930M 840M 620M
Other Income Expense Net
0 0 0 0 0
EBIT
850M 940M 930M 840M 620M
Interest Income
70M 38M 37M 57M 61M
Pretax Income
840M 920M 950M 800M 540M
Income Tax
120M -150M 630M 120M 82M
Minority Interest
0 0 0 0 0
Net Income
720M 1.1B 320M 680M 460M
Net Income Basic
720M 1.1B 320M 680M 460M
20 ← 16 2020 2019 2018 2017 2016
Current cash
1.4B 1.4B 2.2B 2.7B 2.3B
Short term investments
220M 200M 190M 190M 180M
Receivables
1B 930M 780M 720M 630M
Inventory
720M 680M 640M 580M 530M
Other current assets
220M 200M 190M 190M 180M
Current assets
3.4B 3.2B 3.8B 4.2B 3.6B
Long term investments
6.2B 6.3B 4.7B 4.3B 4.2B
Property plant equipment
850M 850M 820M 760M 640M
Goodwill
3.6B 3.6B 3B 2.6B 2.5B
Intangible assets
830M 1.1B 490M 360M 410M
Other assets
780M 610M 340M 390M 470M
Total assets
9.6B 9.5B 8.5B 8.4B 7.8B
Accounts payable
350M 350M 340M 310M 260M
Current long term debt
75M 620M 0 210M 0
Other current liabilities
1B 1.1B 830M 750M 690M
Total current liabilities
1.5B 2.1B 1.2B 1.3B 950M
Long term debt
2.3B 1.8B 1.8B 1.8B 1.9B
Other liabilities
1B 830M 1B 530M 700M
Minority Interest
0 0 4M 4M 3M
Total Liabilities
4.8B 4.7B 4B 3.6B 3.6B
Common stock
310M 310M 320M 320M 330M
Retained earning
81M -18M -340M -130M 6.1B
Treasury stock
0 0 0 0 -11B
Capital surplus
Shareholder equity
4.9B 4.7B 4.6B 4.8B 4.2B
Net tangible assets
440M 48M 1.1B 1.9B 1.3B
20 ← 16 2020 2019 2018 2017 2016
Net Income
720M 1.1B 320M 680M 460M
Depreciation
310M 240M 210M 210M 250M
Changes in receivables
110M 150M 52M 93M 25M
Changes in inventories
41M 41M 63M 42M -8M
Cash change
59M -870M -430M 390M 290M
Cash flow
920M 1B 1.1B 890M 790M
Capital expenditures
-120M -160M -180M -180M -140M
Investments
Investing activity other
Total investing cash flows
-150M -1.6B -700M -310M -240M
Dividends paid
Net borrowings
700M 830M -640M -860M -560M
Other financing cash flows
Cash flow financing
-720M -300M -800M -200M -270M
Exchange rate effect